- Home
- ALNY vs KMI Comparison
ALNY vs KMI Comparison
Compare ALNY & KMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- KMI
- Stock Information
- Founded
- ALNY 2002
- KMI 1936
- Country
- ALNY United States
- KMI United States
- Employees
- ALNY N/A
- KMI N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- KMI Natural Gas Distribution
- Sector
- ALNY Health Care
- KMI Utilities
- Exchange
- ALNY Nasdaq
- KMI Nasdaq
- Market Cap
- ALNY 59.2B
- KMI 59.2B
- IPO Year
- ALNY 2004
- KMI 2011
- Fundamental
- Price
- ALNY $459.28
- KMI $26.82
- Analyst Decision
- ALNY Strong Buy
- KMI Buy
- Analyst Count
- ALNY 27
- KMI 15
- Target Price
- ALNY $420.73
- KMI $29.53
- AVG Volume (30 Days)
- ALNY 1.1M
- KMI 12.7M
- Earning Date
- ALNY 10-30-2025
- KMI 10-15-2025
- Dividend Yield
- ALNY N/A
- KMI 4.42%
- EPS Growth
- ALNY N/A
- KMI 11.35
- EPS
- ALNY N/A
- KMI 1.22
- Revenue
- ALNY $2,461,963,000.00
- KMI $15,969,000,000.00
- Revenue This Year
- ALNY $58.97
- KMI $11.25
- Revenue Next Year
- ALNY $38.81
- KMI $5.46
- P/E Ratio
- ALNY N/A
- KMI $21.72
- Revenue Growth
- ALNY 5.01
- KMI 3.97
- 52 Week Low
- ALNY $205.87
- KMI $20.56
- 52 Week High
- ALNY $469.81
- KMI $31.48
- Technical
- Relative Strength Index (RSI)
- ALNY 70.91
- KMI 48.26
- Support Level
- ALNY $444.66
- KMI $26.22
- Resistance Level
- ALNY $458.30
- KMI $27.09
- Average True Range (ATR)
- ALNY 10.97
- KMI 0.43
- MACD
- ALNY -3.77
- KMI 0.04
- Stochastic Oscillator
- ALNY 71.78
- KMI 66.34
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About KMI Kinder Morgan Inc.
Kinder Morgan is one of the largest midstream energy firms in the US, with an interest in or an operator on more than 80,000 miles of gas, refined products, and carbon dioxide pipelines. The company also owns one of the largest portfolios of gas and refined products storage and terminals. Most of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.